The LIPSIA-STRATEGY study reveals CAAS-vFFR guided revascularization is as effective as traditional pressure wire methods, benefiting both patients and practitioners.

The LIPSIA-STRATEGY trial marks a significant advancement in revascularization techniques, showing that CAAS vFFR guidance offers similar outcomes to pressure wire methods.

The LIPSIA-STRATEGY trial demonstrates that revascularization guided by CAAS vFFR is as effective as traditional methods, providing a less invasive option for patients.

The LIPSIA-STRATEGY trial confirms that angiography-based CAAS vFFR guided revascularization is as effective as wire-based methods, enhancing patient safety and procedure efficiency.

The FAST III trial reveals that the CAAS vFFR, a non-invasive method for assessing coronary lesions, matches the effectiveness of invasive pressure wire techniques, promising patient benefits.

The FAST III study provides significant evidence that CAAS vFFR offers comparable results to traditional wire-based FFR, enhancing cardiac treatment options.

The recent FAST III trial demonstrates that CAAS vFFR provides non-inferior results compared to traditional invasive FFR, offering a safer, minimally invasive alternative for patients.

Discover the groundbreaking results of the FAST III trial comparing CAAS vFFR to traditional methods, promising safer and less invasive cardiac assessments.

The FAST III study reveals that the CAAS vFFR method provides comparable results to the invasive pressure wire FFR for guiding coronary revascularization. This finding has significant implications for patient treatment.

FAST III a été lancé il y a cinq ans pour évaluer si la revascularisation guidée par la FFR angiographique utilisant le CAAS vFFR (vessel Fractional Flow Reserve) donne des résultats thérapeutiques comparables à ceux obtenus avec la FFR à fil de pression. Un résultat positif non inférieur...

El estudio FAST III se inició hace cinco años para evaluar si la revascularización guiada por FFR basada en angiografía, utilizando CAAS vFFR (Reserva Fraccional de Flujo Vascular), ofrece resultados terapéuticos comparables a los obtenidos con FFR basada en catéter de presión. El...

FAST III was initiated five years ago to evaluate whether revascularization guided by angiography–based FFR using CAAS vFFR (vessel Fractional Flow Reserve) delivers therapeutic outcomes comparable to those achieved with pressure wire–based FFR. Positive non-inferior result validates...

FAST III wurde vor fünf Jahren ins Leben gerufen, um zu untersuchen, ob Revaskularisationen, die durch angiographiegestützte FFR unter Verwendung der CAAS vFFR (vessel Fractional Flow Reserve) durchgeführt werden, vergleichbare therapeutische Ergebnisse liefern wie die mit...

FAST III was initiated five years ago to evaluate whether revascularization guided by angiography–based FFR using CAAS vFFR (vessel Fractional Flow Reserve) delivers therapeutic outcomes comparable to those achieved with pressure wire–based FFR. Positive non-inferior result validates...